Xeomin Injection, Powder, Lyophilized, For Solution
NDC Package 46783-165-01
Package Information
Xeomin (incobotulinumtoxina) injection is xEOMIN is contraindicated in patients with:Known hypersensitivity to any botulinum toxin product or to any of the components in the formulation [see Warnings and Precautions (5.3) and Description (11)].Infection at the proposed injection site(s) because it could lead to severe local or disseminated infection. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Merz North America, Inc., this product is identified by NDC 46783-165 and is authorized under FDA application BLA125360.
Identification & Billing
- RxCUI: 1009456 - incobotulinumtoxinA 100 UNT Injection
- RxCUI: 1009459 - incobotulinumtoxinA 50 UNT Injection
- RxCUI: 1732157 - XEOMIN 50 UNT Injection
- RxCUI: 1732157 - incobotulinumtoxinA 50 UNT Injection [Xeomin]
- RxCUI: 1732157 - Xeomin 50 UNT Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 46783 - Merz North America, Inc.
- 46783-165 - Xeomin
- 46783-165-01 - 1 VIAL, SINGLE-USE in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE
- 46783-165 - Xeomin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 46783-165-01 identifies a specific commercial package of 1 vial, single-use in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial, single-use of Xeomin, a human prescription drug labeled by Merz North America, Inc.. This injection, powder, lyophilized, for solution is formulated for intramuscular use and contains botulinum toxin type a as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Merz North America, Inc. on August 01, 2011. The current certification is valid through December 31, 2027.
How is this Merz North America, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 46783016501. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.